NCT01701622

The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University of Mississippi Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Hyperuricemia (high uric acid level) has been correlated to hypertension (high blood pressure) and overall cardiovascular disease risk in several studies. The relationship has even been noted to be independent of metabolic syndrome and kidney function. It has been repeatedly noted that hyperuricemia was an independent risk factor of death in those at high cardiovascular disease risk. A recent review concluded that there is strong evidence that hyperuricemia and gout are coupled with atherosclerosis and cardiovascular events. Although this correlation of hypertension and hyperuricemia is known, there has only been one published study that has evaluated if lowering the uric acid would reduce the blood pressure. The authors concluded that in newly diagnosed hypertensive adolescents, allopurinol decreased the blood pressure. Despite this, further evaluation of this therapeutic approach has not been studied. The hypothesis of this study is that febuxostat, a new xanthine oxidase inhibitor, has blood pressure lowering effects superior to allopurinol in patients diagnosed with gout.

Detailed description

Screening and Recruitment * Identify and recruit 20 participants from the University of Mississippi Medical Center General Internal Medicine/Hypertension and Family Medicine Clinics. * Participants must be currently taking allopurinol for the treatment of gout and be on a stable dose of allopurinol for at least 2 months. * Any antihypertensive medications must be at stable doses for at least 2 months. * The identified patients will be invited to participate in the study. Provide Consent * IRB approved comprehension survey will be administered to participants in determination of competency to provide consent. * The "Consent to Participate in Research" information will be discussed with each participant and consent acquired. * Materials can be taken by the potential participant to review and consent provided at a later date. Data collection * After consent is provided, study personnel will evaluate blood pressure (BP). * Participants will undergo 24-hour Ambulatory Blood Pressure Monitor (ABPM). The normal fee for ABPM will be waived. * Participants will then discontinue allopurinol and initiate febuxostat at a comparable dose. Febuxostat will be provided to all participants at no cost. * If receiving \< 300 mg allopurinol daily, will provide febuxostat 40 mg daily. * If receiving \> 300 mg allopurinol daily, will provide febuxostat 80 mg daily. * After at least 4 weeks of febuxostat, the participant will repeat 24-hour ABPM. The normal fee for ABPM will be waived. * After completion of the febuxostat portion of the study, participants will receive a compensation of $50 at the end of the study. Compensation will only be provided to those who complete the entire study. Results * Data collection will be added to participant's permanent medical records. * Results for individual participants will be discussed with the participant as well as their primary care provider. * The decision to remain on febuxostat or resume allopurinol will lie with the primary care provider.

Conditions

• Blood Pressure
• Gout

Interventions

Type	Name	Description
DRUG	febuxostat	If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily. If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily. Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks.

Timeline

• Start date: 2010-01-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2012-10-05
• Last updated: 2018-01-12
• Results posted: 2013-02-11

Locations

1 site across 1 country: United States